Yasin Keshvargar
Lawyers
Filters
Insulet $419 million repurchases of convertible senior notes
We advised the agent on the transaction
Insulet $450 million senior notes offering
The high-yield notes are due 2033
Spirit Airlines emerges from chapter 11
We advised Spirit in connection with its chapter 11 cases
Beam Therapeutics $500 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Denali Therapeutics $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing